Literature DB >> 9951906

Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation.

U J Tietge1, K H Boker, M J Bahr, S Weinberg, R Pichlmayr, H H Schmidt, M P Manns.   

Abstract

BACKGROUND/AIMS: The liver plays a central role in the production and metabolism of lipoproteins, regulating their synthesis and degradation. The protein content of the lipoproteins are the so-called apolipoproteins. Some of the apolipoproteins serve as cofactors for enzymatic reactions, as ligands for interaction with specific receptors, and as structural proteins. Apolipoprotein B (apoB) is the primary structural component of the atherogenic low density lipoprotein (LDL) particles and has a specific binding region for interacting with the LDL-receptor. In contrast, apolipoprotein A-I (apoA-I) represents the primary protein content of the high density lipoprotein (HDL) particles, which interacts with the putative HDL-receptor, and stimulates the enzymatic reaction of lecithin-cholesterol acyltransferase (LCAT) resulting in esterified cholesterol, which is the essential step in the process of reverse cholesterol transport.
METHODOLOGY: We studied lipid parameters in arterial and hepatic venous serum samples from 52 patients with cirrhosis and from 16 patients in the clinically stable long-term course after liver transplantation. Splanchnic blood flow was measured (indocyanine-green steady-state infusion) and hepatic extraction/production rates were calculated. To assess the influence of the clinical stage of established cirrhosis, the quantitated parameters were statistically analyzed.
RESULTS: In cirrhosis, apolipoprotein A-I levels are decreased depending on the clinical stage (p<0.01). This parameter showed excellent correlations to liver function tests. Triglycerides (TG) (p<0.05) and cholesterol (Chol) (p<0.05) were reduced as well, whereas apolipoprotein B levels did not change. In cirrhosis, hepatic production of both cholesterol and triglycerides were decreased (p<0.05 each), as well as hepatic extraction of free fatty acids (FFA) (p<0.01). Except for cholestatic liver disease with raised serum cholesterol (p<0.05) and apolipoprotein B levels (p<0.001), the etiology of cirrhosis had no impact on the observed serum lipid alterations.
CONCLUSIONS: The serum concentrations of the determined lipid parameters depend primarily on liver function. Decreased liver function was associated with reduced extraction of free fatty acids and reduced cholesterol and triglyceride synthesis. Liver transplantation restored the lipid abnormalities to normal. Finally, apolipoprotein A-I served as an excellent parameter for predicting liver function in the studied patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9951906

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  16 in total

Review 1.  Metabolism of high density lipoproteins in liver cancer.

Authors:  Jing-Ting Jiang; Ning Xu; Chang-Ping Wu
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

2.  Impaired plasma lipid profiles in acute hepatitis.

Authors:  Libo Luo; Xiangke Pu; Yongzhong Wang; Ning Xu
Journal:  Lipids Health Dis       Date:  2010-01-23       Impact factor: 3.876

3.  Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease.

Authors:  Lauren N Bell; Janice L Theodorakis; Raj Vuppalanchi; Romil Saxena; Kerry G Bemis; Mu Wang; Naga Chalasani
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 4.  Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.

Authors:  Graziella Privitera; Luisa Spadaro; Simona Marchisello; Giuseppe Fede; Francesco Purrello
Journal:  Dig Dis Sci       Date:  2017-11-25       Impact factor: 3.199

5.  Proteomic analysis for developing new biomarkers of hepatocellular carcinoma.

Authors:  Maria Pleguezuelo; Laura M Lopez-Sanchez; Antonio Rodriguez-Ariza; Jose L Montero; Javier Briceno; Ruben Ciria; Jordi Muntane; Manuel de la Mata
Journal:  World J Hepatol       Date:  2010-03-27

6.  Proteomic Profiling of Liver and Plasma in Chronic Ethanol Feeding Model of Hepatic Alcohol Dehydrogenase-Deficient Deer Mice.

Authors:  Kamlesh K Bhopale; Samir M Amer; Lata Kaphalia; Kizhake V Soman; John E Wiktorowicz; Ghulam A Shakeel Ansari; Bhupendra S Kaphalia
Journal:  Alcohol Clin Exp Res       Date:  2017-09-08       Impact factor: 3.455

7.  Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation.

Authors:  Valeria R Mas; Daniel G Maluf; Kellie J Archer; Kenneth Yanek; Karen Bornstein; Robert A Fisher
Journal:  Transplantation       Date:  2009-01-15       Impact factor: 4.939

Review 8.  Lipids changes in liver cancer.

Authors:  Jing-Ting Jiang; Ning Xu; Xiao-Ying Zhang; Chang-Ping Wu
Journal:  J Zhejiang Univ Sci B       Date:  2007-06       Impact factor: 3.066

Review 9.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

10.  Association of apolipoprotein E with the progression of hepatitis B virus-related liver disease.

Authors:  Yueshuang Shen; Meng Li; Xiongwei Ye; Qihua Bi
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.